Most Active Biotech Investors in San Francisco 2026

10 firms writing Biotech checks in San Francisco, led by Sofinnova Investments, AME Cloud Ventures.

Biotech in San Francisco accounts for 25 tracked companies with verified cap-table data, 25 of which disclose round sizes totalling $5.1B. The median disclosed raise is $165M, and the largest is Xaira Therapeutics at $1B, ahead of NewLimit ($682M) and Delfi Diagnostics ($400M).

The names that recur most often on these biotech cap tables are Founders Fund (3 companies), Cultivian Sandbox Ventures (3 companies), SOSV (3 companies), Lux Capital (3 companies), Kleiner Perkins (2 companies), Eli Lilly (2 companies). By latest disclosed round, the market skews Series B (8), Series A (6), Series C (3), Series D (3).

Best funded Biotech in San Francisco companies

  1. Xaira Therapeutics — $1B (latest: Series A)
  2. NewLimit — $682M (latest: Series C)
  3. Delfi Diagnostics — $400M (latest: Series B)
  4. InterVenn — $279M (latest: Series C)
  5. HELIX — $225M (latest: Series D)
  6. Dispatch Bio — $216M (latest: Series A)
  7. AIRNA — $215M (latest: Series B)
  8. Cerevance — $204M (latest: Series B)
  9. Chai Discovery — $200M (latest: Series B)
  10. Marea Therapeutics — $190M (latest: Series B)
  11. Verge Genomics — $180M (latest: Seed)
  12. CytoVale — $180M (latest: Series D)
  13. Expedition Therapeutics — $165M (latest: Series A)
  14. Geltor — $137M
  15. CytomX Therapeutics — $136M (latest: IPO)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library